hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06349122, orgStudyIdInfo id: 2023-509421-41-00, briefTitle: Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth, acronym: AUTOP2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2027-03, completionDateStruct date: 2028-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Assistance Publique Hopitaux De Marseille, class: OTHER, descriptionModule briefSummary: Preterm birth is an important cause of death and disabilities. Bacterial vaginosis (BV) is a common vaginal dysbiosis or abnormal microbiota, with a predominance of anaerobic bacteria with a lack of Lactobacillus, with various diagnosis methods. Often asymptomatic, BV increases the risk of preterm birth according to the gestational age at diagnosis. BV is usually diagnosed by conventional diagnosis such as Nugent score. Molecular diagnosis of BV has been demonstrated to be more reproducible, more accurate and to better define dysbiosis.The main objective of the study is to evaluate the effectiveness of an innovative screen-and-treat strategy for vaginal flora abnormalities by molecular biology using a Point of Care multiplex technology before 18 weeks' gestation to reduce the rate of preterm birth in a population of pregnant women at high risk of preterm birth.The hypothesis is that a strategy for screening and treating vaginal flora abnormalities and their recurrences using molecular biology in women with a history of prematurity or late-term abortion could be effective in reducing premature births by 40%., conditionsModule conditions: Bacterial Vaginosis, conditions: Vaginal Dysbiosis, conditions: Premature Delivery, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1292, type: ESTIMATED, armsInterventionsModule interventions name: Vaginal flora abnormalities screening and quantification using molecular biology technique, interventions name: Azithromycine, interventions name: Ceftriaxone, interventions name: Metronidazole, interventions name: Clotrimazole, Vaginal, interventions name: Usual Care, outcomesModule primaryOutcomes measure: The rate of preterm birth, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06349109, orgStudyIdInfo id: PA-WPW, briefTitle: Physical Activity in Children With Wolff-Parkinson-White Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Karamanoğlu Mehmetbey University, class: OTHER, descriptionModule briefSummary: The aim of this study was to investigate the level of physical activity and its determinants in children with WPW., conditionsModule conditions: Wolff-Parkinson-White Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Cardiopulmonary exercise test, interventions name: Atrial-Ventricular Strain Analysis, interventions name: Arterial Stiffness Measurement, interventions name: Physical Activity Level, interventions name: Physical Activity Barriers Assesment, outcomesModule primaryOutcomes measure: The Physical Activity Questionnaire for Older Children Score, secondaryOutcomes measure: VO2peak, secondaryOutcomes measure: aPWV, secondaryOutcomes measure: GLS, secondaryOutcomes measure: LASr, secondaryOutcomes measure: LASct, secondaryOutcomes measure: LAScd, secondaryOutcomes measure: Physical activity barriers (Parent) scale score, secondaryOutcomes measure: Physical Activity Outcome Expectancies (Child) scale score, secondaryOutcomes measure: Physical Activity Home Environment (Child) scale score, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Hacettepe University, status: RECRUITING, city: Ankara, country: Turkey, contacts name: Haluk Tekerlek, PhD, role: CONTACT, phone: +905355915009, email: haluktekerlek@gmail.com, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06349096, orgStudyIdInfo id: ALM-HAR-CLL-23-01, briefTitle: Safety And Efficacy Investigation Of The Effects Of ClearLift Q-Switched Nd:Yag 1064nm Laser Module In The Treatment Of Facial Skin Wrinkles, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Alma Lasers, class: INDUSTRY, descriptionModule briefSummary: Alma Lasers ClearLift is a fractional non-ablative Q-Switched laser, allowing practitioners to use the benefits of a high intensity QS laser for the treatment of aged skin. Alma Harmony ClearLift uses a fractional QS laser to achieve a deep mechanical effect beneath the epidermis via a photoacustic effect. This creates a controlled dermal wound while leaving the epidermis intact. The wound healing process stimulates growth of new collagen, skin contracture and tightening. This procedure is virtually painless with no downtime and is safe for all skin types.Based on this background, we have considered an interest to design a study aimed at assessing the efficacy and safety of a treatment course with ClearLift Module in patients with facial skin wrinkles, conditionsModule conditions: Facial Skin Wrinkles, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Alma Harmony, outcomesModule primaryOutcomes measure: Primary endpoint, secondaryOutcomes measure: Secondary endpoint, secondaryOutcomes measure: Secondary endpoint, secondaryOutcomes measure: Secondary endpoint, otherOutcomes measure: Safety & Tolerability, otherOutcomes measure: Safety & Tolerability, eligibilityModule sex: FEMALE, minimumAge: 35 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: San Luca Medical Clinic, city: Tirana, country: Albania, contacts name: Arminda Avdulaj, MD, role: CONTACT, phone: 694488000, phoneExt: +355, email: avdulajarminda@gmail.com, contacts name: Arminda Avdulaj, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.3275, lon: 19.81889, hasResults: False
protocolSection identificationModule nctId: NCT06349057, orgStudyIdInfo id: AnkaraCHBilkent.1, briefTitle: The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Ankara City Hospital Bilkent, class: OTHER, descriptionModule briefSummary: Many drugs have anticholinergic activity. This means that it blocks the muscarinic binding of the neurotransmitter acetylcholine.In this study, the anticholinergic burden of the patients in the perioperative period will be calculated with the Anticholinergic Cognitive Burden Scale (ACBS) and patients with a score of 1 or above will be included in the study. Anticholinergic load of drugs used in the intraoperative period; Its effect on postoperative hospital stay, morbidity and mortality following elective heart surgery will be investigated., conditionsModule conditions: Mortality, conditions: Postoperative Complications, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: reducing anticholinergic burden, outcomesModule primaryOutcomes measure: Mortality, secondaryOutcomes measure: Effects on postoperative recovery, secondaryOutcomes measure: Effects on postoperative recovery, secondaryOutcomes measure: Postoperative complication, otherOutcomes measure: Length of stay in hospital and intensive care unit, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Seda Kurtbeyoğlu, status: RECRUITING, city: Çankaya, state: Ankara, zip: 06800, country: Turkey, contacts name: Seda Kurtbeyoğlu, role: CONTACT, phone: +905388342776, email: kurtbeyogluseda@gmail.com, geoPoint lat: 39.9179, lon: 32.86268, hasResults: False
protocolSection identificationModule nctId: NCT06349044, orgStudyIdInfo id: BASIMA, briefTitle: A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Zhejiang Cancer Hospital, class: OTHER, descriptionModule briefSummary: Based on the interaction between radiation therapy and immunotherapy and the potential potentiation of Probio-M9 for the treatment of ICIs, this study is planned to design an integrated treatment protocol for the first-line treatment of advanced gastrointestinal tumors through the use of macrofractionated radiotherapy as a means of immune activation, combined with the synergistic effect of Probio-M9 microbial agents and PD-1 inhibitors., conditionsModule conditions: Gastroesophageal Junction Adenocarcinoma, conditions: Liver Cancer Stage IV, conditions: Biliary Tract Cancer, conditions: Pancreatic Adenocarcinoma, conditions: Colorectal Cancer, conditions: Gastric Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Hypofractionated radiotherapy/SBRT（5-8 Gy/fx，3-5 fx）, interventions name: Anti-PD-1 monoclonal antibody, interventions name: Oxaliplatin and Capecitabine, interventions name: Anti-VEGF 15mg/kg, interventions name: Anti-VEGF 7.5mg/kg, interventions name: Gemcitabine and Cisplatin, interventions name: Gemcitabine and Albumin paclitaxel, outcomesModule primaryOutcomes measure: ORR, secondaryOutcomes measure: ORR, secondaryOutcomes measure: adverse effects rate, secondaryOutcomes measure: Qol, secondaryOutcomes measure: PFS, secondaryOutcomes measure: OS, secondaryOutcomes measure: Qol, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhengjiang Cancer Hospital, status: RECRUITING, city: Hangzhou, state: Zhejiang, country: China, contacts name: Ji Zhu, role: CONTACT, phone: 13501978674, email: zhuji@zjcc.org.cn, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06349018, orgStudyIdInfo id: IRB-2023-972, briefTitle: Effects of Isotonic Beetroot Supplementation on Sprint Interval Exercise Performance, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-20, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Nanyang Technological University, class: OTHER, descriptionModule briefSummary: This study aims to examine the effects of dietary nitrate supplementation via beetroot juice on sprint interval cycling exercise performance. Twenty-four participants (male or female) will undertake a randomized, crossover trial where they consume either (i) an isotonic beetroot juice drink containing nitrate (12.9 mmol) for 5 days or (ii) an isotonic sports drink (no nitrate) for 5 days. On Day 5 of each trial, participants will come to the laboratory and 2 hours after consuming their allocated drink will complete a 6 bouts of sprint interval exercise. Power output during cycling will be measured as the primary outcome measure. Salivary and plasma measures of nitrate and nitrite will be taken over the course of the morning on Day 5. After a 5-day washout period participants will crossover and begin their second trial., conditionsModule conditions: Exercise Performance, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, maskingDescription: Both isotonic drinks (high nitrate or no nitrate) are deidentified and labelled (coded) by a third party not involved with the research. Randomization and allocation are completed by a third party not involved in the testing., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Dietary Supplement: High nitrate isotonic drink, interventions name: Dietary Supplement: No nitrate isotonic drink, outcomesModule primaryOutcomes measure: Power output during maximal sprint cycling, secondaryOutcomes measure: Salivary nitrate, secondaryOutcomes measure: Plasma nitrate and nitrite, secondaryOutcomes measure: Muscle oxygenation, secondaryOutcomes measure: Sensory evaluation (Acceptance and Preference Test Evaluation by Meilgaard et al 2007), secondaryOutcomes measure: Stroop test, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Human Bioenergetics Laboratory, National Institute of Education, Nanyang Technological University, status: RECRUITING, city: Singapore, zip: 637616, country: Singapore, contacts name: Stephen Burns, PhD, role: CONTACT, phone: 65 67903354, email: stephen.burns@nie.edu.sg, geoPoint lat: 1.28967, lon: 103.85007, hasResults: False
protocolSection identificationModule nctId: NCT06349005, orgStudyIdInfo id: 111, briefTitle: Laryngoscopy and Coronary Artery Bypass Graft Surgery, acronym: VL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Konya Meram State Hospital, class: OTHER, descriptionModule briefSummary: In this prospective, randomized, controlled trial, the purpose is to compare Macintosh laryngoscope, EzVision® video laryngoscope, McGrath® video laryngoscope and Storz® video laryngoscope in terms of hemodynamic response associated with intubation in adult patients undergoing Coronary Artery Bypass Surgery (CABG)., conditionsModule conditions: Videolaryngoscopy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 112, type: ESTIMATED, armsInterventionsModule interventions name: Tracheal intubation using Storz VL, interventions name: Tracheal intubation using Macintosh laryngoscopy, interventions name: Tracheal intubation using MacGrath VL, interventions name: Tracheal intubation using EzVision VL, outcomesModule primaryOutcomes measure: Hemodynamic response, primaryOutcomes measure: Hemodynamic response, secondaryOutcomes measure: Intubation time, secondaryOutcomes measure: Visualization of the glottis, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Betul Kozanhan, city: Konya, zip: 42005, country: Turkey, geoPoint lat: 37.87135, lon: 32.48464, hasResults: False
protocolSection identificationModule nctId: NCT06348992, orgStudyIdInfo id: HMUDQ20240318001, briefTitle: ACT Combined Yoga for Parental Burnout in Parents With Autistic Children, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Harbin Medical University, class: OTHER, descriptionModule briefSummary: OBJECTIVE: To explore the intervention effect of ACT combined with a yoga intervention program on parenting burnout in parents with ASD.METHODS: This study used a combination of qualitative research and quantitative analysis to examine the intervention effects of an ACT-centered intervention program on parenting burnout in parents of children with ASD, and to clarify the evaluations and perceptions of parents with ASD about the research program through qualitative research.RESULTS AND CONCLUSION: To clarify the intervention effect of ACT combined with yoga intervention program on parenting burnout of ASD parents., conditionsModule conditions: Autism Spectrum Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Acceptance commitment therapy and yoga, interventions name: Active Comparator: Mental Health Education Group, outcomesModule primaryOutcomes measure: Measuring parental Burnout Levels, primaryOutcomes measure: Measuring parenting stress Levels, secondaryOutcomes measure: Patient-Reported Outcomes Measurement Information System adult profile-57, PROMIS-57, secondaryOutcomes measure: Medical Outcomes Study 36-Item Short-Form Health Survey, MOS SF-36, secondaryOutcomes measure: Acceptance and Action Questionnaire-II, AAQ-II, secondaryOutcomes measure: Cognitive Fusion Questionnaire，CFQ-F, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Harbin Medical University Hospital, status: RECRUITING, city: Daqing, state: None Selected, zip: 043300, country: China, contacts name: Jiayi Chen, Master, role: CONTACT, phone: 15765962070, email: cjy071949@163.com, geoPoint lat: 46.58333, lon: 125.0, hasResults: False
protocolSection identificationModule nctId: NCT06348979, orgStudyIdInfo id: CEBD 5/2021, briefTitle: Clinical Performance of Fiber Reinforced FRC Base and Bonded CAD/CAM Resin Composite Endocrowns, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2023-12-30, completionDateStruct date: 2024-01-30, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: This research proposal is introduced to clinically test short fiber reinforced flowable resin composite material (everX Flow, GC Europe) as a supporting base under CAD/CAM resin composite endocrowns due to gap of knowledge present in this area., conditionsModule conditions: Dental Caries, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 110, type: ACTUAL, armsInterventionsModule interventions name: Fiber flowable (SFRC) support below hybrid nanoceramic endocrowns, interventions name: all ceramic Endocrowns (emax), outcomesModule primaryOutcomes measure: clinical Fracture, secondaryOutcomes measure: clinical performance marginal adaptation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 38 Years, stdAges: ADULT, contactsLocationsModule locations facility: Cairo University, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06348966, orgStudyIdInfo id: predictors of readmission, briefTitle: Predictors of Hospital Readmission for Chronic Obstructive Pulmonary Disease Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-05, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: This study is aimed to determine the risk factors for hospital readmission within 6 months in COPD patients, conditionsModule conditions: Hospital Radmission for COPD Patients, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 188, type: ESTIMATED, outcomesModule primaryOutcomes measure: assessment of potential predictors of readmission among COPD patients, secondaryOutcomes measure: development of early warning model for hospital readmission in COPD patients, eligibilityModule sex: ALL, minimumAge: 25 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False